Non-antibiotic drugs with the greatest observed risks for C. difficile infection were antidiarrheals, analgesics, and ...

Researchers say the reduction was influenced by the combined effects of changes in infection prevention and control, ...

The bacterium Clostridium difficile — otherwise known as C. diff — spreads within intensive care units more than three times as much as previously thought, according to a study published on April 4 in ...

Study results suggest the greatest risk for Clostridioides difficile infection was observed with use of clindamycin while the lowest risk was observed with doxycycline and minocycline. Results of the ...

The hospital-acquired infection Clostridium difficile, which causes inflammation of the colon and can be deadly among elderly patients, may be spread outside the hospital setting via food, according ...

Key Takeaways Prompt treatment with fecal transplant can improve survival among critically ill C. difficile patients14 of 18 ...

For the study, researchers at the Fargo (N.D.) VA Healthcare System allowed hospital nurses to independently order stool samples for patients displaying C. diff symptoms without requiring a ...

A new study looked at Clostridioides difficile infection (CDI) in outpatient settings and found the bacteria may be underdiagnosed, according to a study out Jan. 11 in Open Forum Infectious Diseases.

Two gastroenterologists spoke with Becker’s to discuss research challenges, advice for early-career physicians and more. Paul Feuerstadt, MD, is a practicing gastroenterologist at the ...

The prevalence of Clostridioides difficile has risen in recent years, and although its carriage is recognized in infancy, limited data exist on its longitudinal trends. Results of a large longitudinal ...

After suffering repeated bouts of debilitating Clostridium difficile infections, many patients significantly change their behaviors, but some precautions may do little to prevent future infections, ...

After reporting non-statistically significant results in it a phase-II study, Cambridge, Mass.-based Seres Therapeutics is launching a revised phase-II study for its SER-109 Clostridium Difficile ...